Altimmune Prices $225 Mln Oversubscribed Public Offering Of Shares And Warrants; Stock Down

Altimmune priced an oversubscribed public offering of 64.25 million shares and warrants, expected to raise approximately $225 million in gross proceeds. The deal adds significant capital to the late-stage biopharmaceutical company, but it is also dilutive to existing shareholders. The news is material for ALT shares, though primarily a financing event rather than an operating update.

Analysis

Altimmune priced an oversubscribed public offering of 64.25 million shares and warrants, expected to raise approximately $225 million in gross proceeds. The deal adds significant capital to the late-stage biopharmaceutical company, but it is also dilutive to existing shareholders. The news is material for ALT shares, though primarily a financing event rather than an operating update.